Svájc - francia - Swissmedic (Swiss Agency for Therapeutic Products)

boiron sa - artemisia eberraate - tm, d; tm, d - homöopathisch

Svájc - francia - Swissmedic (Swiss Agency for Therapeutic Products)

boiron sa - artemisia eberraate - k30, d; lm/q1, d - homöopathisch

Kanada - francia - Health Canada

hoffmann-la roche limited - casirivimab; imdévimab - solution - 1332mg; 1332mg - casirivimab 1332mg; imdévimab 1332mg - monoclonal antibodies

Kanada - francia - Health Canada

hoffmann-la roche limited - casirivimab; imdévimab - solution - 300mg; 300mg - casirivimab 300mg; imdévimab 300mg - monoclonal antibodies

Európai Unió - francia - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - agents antinéoplasiques - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Európai Unió - francia - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - des sérums et immunoglobulines, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. voir les sections 4. 4 et 5.

Kanada - francia - Health Canada

astrazeneca canada inc - tixagévimab; cilgavimab - solution - 150mg; 150mg - tixagévimab 150mg; cilgavimab 150mg

Kanada - francia - Health Canada

glaxosmithkline inc - bélimumab - poudre pour solution - 120mg - bélimumab 120mg - immunosuppressive agents

Kanada - francia - Health Canada

glaxosmithkline inc - bélimumab - poudre pour solution - 400mg - bélimumab 400mg - immunosuppressive agents

Kanada - francia - Health Canada

glaxosmithkline inc - bélimumab - solution - 200mg - bélimumab 200mg - immunosuppressive agents